ClinVar Miner

Submissions for variant NM_000152.5(GAA):c.2238G>A (p.Trp746Ter) (rs1800312)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel, ClinGen RCV000410158 SCV001371729 pathogenic Glycogen storage disease, type II 2020-05-05 reviewed by expert panel curation This variant, c.2238G>A (p.Trp746Ter), is a nonsense variant, predicted to result in nonsense mediated decay and lack of gene product, meeting PVS1. This is supported by the finding that patients with this variant have no GAA cross-reactive immunological material in protein isolated from cultured skin fibroblasts (i.e. CRIM-negative) (PMID 22252923), as well as functional studies in which there was no measurable GAA activity when the variant was expressed in HEK-293 cells (PMID 23430493). The highest population minor allele frequency in gnomAD v2.1.1 is 0.00004 in the African population, meeting PM2. This variant has been reported in 3 patients who meet the ClinGen LSD VCEP's specifications for PP4. Two of these patients are compound heterozygous for pathogenic variants, either c.-32-13T>G or c.1826dupA (PMIDs 16860134, 22613277, 25741864). The phase is unknown. This data meets PM3. Another patient is compound heterozygous for the variant and c.1843G>A (p.Gly615Arg). This in trans data was used in the assessment of p.Gly615Arg and therefore was not included here in order to avoid circular logic. There is a ClinVar entry for this variant (ClinVar variation ID: 270904, 2 star review status) with 3 submitters classifying the variant as pathogenic and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PM3, PP4
Counsyl RCV000410158 SCV000486333 likely pathogenic Glycogen storage disease, type II 2016-05-11 criteria provided, single submitter clinical testing
Invitae RCV000410158 SCV000626551 pathogenic Glycogen storage disease, type II 2019-09-09 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Trp746*) in the GAA gene. It is expected to result in an absent or disrupted protein product. This variant is present in population databases (rs1800312, ExAC 0.002%). This variant has been reported in combination with another GAA variant in several individuals affected with Pompe disease (PMID: 16860134, 22613277, 29122469). ClinVar contains an entry for this variant (Variation ID: 370904). This variant has been reported to affect GAA protein function (PMID: 23430493). Loss-of-function variants in GAA are known to be pathogenic (PMID: 18425781, 22252923). For these reasons, this variant has been classified as Pathogenic.
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000723386 SCV000700286 pathogenic not provided 2017-01-17 criteria provided, single submitter clinical testing
GeneDx RCV000723386 SCV000890192 pathogenic not provided 2018-08-16 criteria provided, single submitter clinical testing The W746X nonsense variant in the GAA gene has been reported previously in multiple unrelated individuals with GSDII(Kishnani et al. (2006; Berrier et al., 2015; Broomfield et al. 2016). This pathogenic variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay.
Broad Institute Rare Disease Group,Broad Institute RCV000410158 SCV001422605 pathogenic Glycogen storage disease, type II 2020-01-22 no assertion criteria provided curation The p.Trp746Ter variant in GAA has been reported in at least 2 Caucasian and 1 Asian individuals with Glycogen Storage Disease II (PMID: 16860134, 22613277, 25741864), and has also been reported likely pathogenic by Counsyl and pathogenic by EGL Genetic Diagnostics, GeneDx, and Invitae in ClinVar (Variation ID: 370904). This variant has been identified in 0.004% (1/24930) of African chromosomes and 0.002% (2/128684) of European (non-Finnish) chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs1800312). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. In vitro functional studies with HEK293 cells transfected with this variant provide some evidence that the p.Trp746Ter variant may impact GAA processing and activity (PMID: 23430493). However, these types of assays may not accurately represent biological function. This nonsense variant leads to a premature termination codon at position 746, which is predicted to lead to a truncated or absent protein. Loss of function of the GAA gene is an established disease mechanism in autosomal recessive Glycogen Storage Disease II. The presence of this variant in combination with a reported pathogenic variant and in an individual with Glycogen Storage Disease II increases the likelihood that the p.Trp746Ter variant is pathogenic (PMID: 22613277). The phenotype of individuals heterozygous for this variant is highly specific for Glycogen Storage Disease II with abnormally low GAA activity detected in an assay of skin fibroblasts (PMID: 16860134, 22613277). One additional pathogenic variant, c.2237G>A (p.Trp746Ter), with the same position and amino acid change has been reported in association with disease (PMID: 26497565, 10206684, 12923862, 16917947, 18429042, 18285536, 21484825, 22980766, 24158270, 22237443, 24169249, 25488666, 25526786, 24269976, 17056254). In summary, this variant meets criteria to be classified as pathogenic for Glycogen Storage Disease II in an autosomal recessive manner based on the predicted impact of the variant and low frequency in the general population. ACMG/AMP Criteria applied: PVS1, PM2, PM3_Supporting, PP4 (Richards 2015).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.